<DOC>
	<DOCNO>NCT02191358</DOCNO>
	<brief_summary>This multicenter observational study aim investigate benefit provide pharmacogenetic test YouScript Personalized Prescribing System include clinical decision support tool individualize pharmacist recommendation elderly polypharmacy patient risk adverse drug event . The YouScript system unique identify drug-gene , drug-drug-gene interaction miss exist system , represent 35 % significant interaction warning . Data analysis ass impact recommendation medication change clinical decision making , patient outcome , healthcare resource utilization determine medication , specialty , patient segment derive great benefit intervention . Data gather patient enrol study compare patient match key characteristic Inovalon 's MORE2 healthcare database .</brief_summary>
	<brief_title>YouScript IMPACT Registry</brief_title>
	<detailed_description>BACKGROUND AND RATIONALE : Genelex Corporation leader comprehensive medication management base YouScript clinical decision support tool DNA drug sensitivity test . Controlling prescription drug adverse event risk complex 85 % patient significant DNA base variation activity cytochrome p450 ( CYP ) enzymes metabolize majority commonly prescribe medicine . Polypharmacy , common elderly chronically ill increase risk adverse drug event ( ADE ) . The public healthcare problem result factor cost estimate $ 289 billion per year excess health care cost . The goal YouScript personalize prescribe system improve patient outcomes prevent ADEs cause drug-drug , drug-gene drug-drug-gene interaction . ADEs define include prescription over-the-counter ( OTC ) drug overdose toxicity , adverse drug reaction ( ADRs ) , treatment failure generally cause properly prescribe medication . The YouScript system prevents ADEs combine analysis patient drug regimen individual genetics . YouScript DNA drug sensitivity test include five enzyme cytochrome P450 ( CYP ) group ( CYP2D6 , CYP2C9 , CYP2C19 , CYP3A4 , CYP3A5 ) . YouScript synthesizes decade publicly fund basic clinical research provide actionable information physician treat patient . Elderly patient great risk ADE . Two-thirds adult age 65 old take one prescription drug daily . Patients age 60 year old account 10-17 % hospitalization 51 % death ADEs , although age group represent 17 % U.S. population . Following discharge , 50 % patient ADRs decline one activity daily live , compare 24 % patient without ADRs . Although value pharmacogenetic test comprehensive gene-based medication management recognize clinician , still endorse many expert committee third party payer prescription drug . The purpose study meet need evidence well demonstrate impact comprehensive gene-based medication management healthcare resource utilization ( HRU ) , clinical decision-making , patient outcome . Therefore , propose study aim assess impact YouScript Personal Prescribing System HRU , clinical decision-making , clinical outcome . OBJECTIVES : Primary objective : To determine impact YouScript Personalized Prescribing System HRU . Secondary objective : To assess impact YouScript Personalized Prescribing System clinical decision-making , include risk modification dosage adjustment medication change . To assess impact YouScript Personalized Prescribing System number ADEs experience patient . STUDY DESIGN : The study design prospective , non-interventional , observational study assess real-world impact YouScript Personalized Prescribing System HRU , provider clinical decision-making , ADEs . The decision utilize YouScript Personalized Prescribing System treatment decision make accordance usual care practice , make prior decision participate study . Outcomes compare group prospectively enrol patient undergo CYP2D6 , CYP2C19 , CYP2C9 , VKORC1 , CYP3A4 , CYP3A5 test YouScript Personalized Prescribing System discretion provider ( i.e . `` tested '' patient ) data group similar patient include Inovalon 's MORE2 healthcare database meeting enrollment criterion ( exclude YouScript test ) match key characteristic test patient use propensity score matching . Sites queried regard use drug-drug interaction ( DDI ) system well distinguish impact YouScript vs. system . The study aim initially enroll 1500 patient 3-15 site United States , identify Genelex . The study may expand 10,000 patient additional site United States . The study duration estimate least 15 month , include 3 month study set-up , 6 month longer patient enrollment depend rate accrual site , 4 month per-patient follow-up 2 month study closeout . A pilot study consist first 150 patient enrol conducted prior continue enrollment order assist plan larger-scale study , confirm appropriate length follow-up necessary observe patient outcome , comparison patient baseline characteristic , identify potential variable propensity score matching , sample size calculation , necessary change case report form . After discussion study study staff provide informed consent , baseline data collect ( described detail ) , include buccal swab blood sample , patient undergo YouScript test . Follow-up data collect 120 day enrollment patient . Patients see clinic phone ( visit schedule 120 day ± 14 day baseline ) query regard HRU ( include number hospitalization , ER visit , provider office visit , procedure ) , change medication , reason change , adverse drug event . This data also abstract medical record completeness . In addition , provider utilize YouScript also survey regard usefulness YouScript clinical decision-making . Similar available data abstract sample presumably untested patient include MORE2 registry database meet eligibility criterion match prospectively enrolled patient key characteristic use propensity score matching . CLINICAL ASSESSMENTS : As observational study , mandatory visit . While time actual patient visit occur discretion treat provider , request data enter baseline 120 day enrollment regardless number time patient see interval . All data collect enter site directly web-based electronic data capture ( EDC ) system via electronic case report form ( eCRFs ) . After patient screen consent , follow variable collect baseline , collect part standard YouScript requisition form : demographic , current smoking status , active medical condition , liver kidney dysfunction , drug interest concomitant medication ( include date initiation therapy , dose , frequency , indication , respectively ) , previous ADEs drug interest , buccal swab/blood sample YouScript testing . The site require enter data collect YouScript requisition form eCRF . The following follow-up data collect routinely schedule visit , phone visit schedule , approximately 120 day enrollment : number hospitalization ; ER visit , diagnostic surgical procedure , office visit since baseline ; Change/consider/monitor recommendation drug regimen change ( ) pharmacy team ; change drug regimen/dose drug interest concomitant medication since baseline ; reason change change drug regimen/dose ; ADEs since baseline ; healthcare provider survey/questions regard role usefulness YouScript clinical decision making . If visit schedule 120 day ±14 day , study staff contact patient telephone data collect . If patient choose terminate participation completion 120-day follow -- ‐up , follow-up data collect , well reason discontinuation . DATA ANALYSIS : Complete analytical specification , include table listing , fully detailed statistical analysis plan ( SAP ) . Descriptive analysis perform gain understanding qualitative quantitative nature data collect characteristic sample study . Summary statistic calculate presented baseline characteristic outcomes test control group separately . Comparative analysis conduct determine whether statistically significant difference specific quantitative outcome test control group . Because propensity score match test control patient , unadjusted comparative analysis perform report primary result . Adjusted analysis use multiple regression model use examine potential confounding effect address match process . Exploratory analysis conduct explore impact YouScript various subgroup identify potential subgroup likely benefit YouScript , deem appropriate . The first interim analysis conduct data collection complete approximately first 150 prospectively enrolled patient ( i.e . pilot study ) determine change necessary method large scale study . The second interim analysis complete data collection complete approximately 750 prospectively enrolled patient . For main analysis , difference HRU 120-day follow-up determine compare mean number hospitalization , emergency room visit , diagnostic procedure , surgical procedure , clinic visit test untested group . The impact YouScript clinical decision making determine compare mean number change drug regimen dose underwent YouScript testing . In addition , number ADEs experience patient 120-day study compare test untested group . Comparisons make t-test ( data normally distribute ) , Wilcoxon-Rank-Sum test ( data continuous normally distribute ) , chi-squared ( Fisher exact ) test data consider categorical . Multivariable linear regression model use examine association YouScript Personalized Prescribing System HRU , clinical decision making , ADEs , respectively , control potential confounding effect baseline characteristic include propensity score matching process . In tested patient , HRU , number ADEs , number change drug regimen/dose examine relationship genotype , sample size permitting . Reasons change drug regimen dose recommendation make summarize qualitatively analyze quantitatively possible . In addition , calculation drug-gene , drug-drug-gene drug-drug interaction recommendation acceptance rate ( define whether drug dose change recommendation make ) calculate . Provider feedback regard whether YouScript Personalized Prescribing System impact clinical decision summarize quantitatively qualitatively .</detailed_description>
	<mesh_term>Drug-Related Side Effects Adverse Reactions</mesh_term>
	<mesh_term>Metabolism , Inborn Errors</mesh_term>
	<criteria>INCLUSION CRITERIA : Prospectively enrol study participant ( i.e . `` tested '' patient ) must fulfill follow criterion eligible enrollment study : Age 65 old Willing able provide inform consent study participation either directly legally authorize representative ( LAR ) Undergoing test YouScript Personalized Prescribing System recommend course routine care , order follow test : CYP2D6 , CYP2C19 , CYP2C9 , VKORC1 , CYP3A4 , CYP3A5 Currently take least 3 prescription medication ( route administration ) Initiated treatment , change dose , least 1 follow oral form medication ( exclude medication take PRN ) within previous 120 day ( generic name give major U.S. brand name give parenthesis ) . These medication subject significant drug‐gene interaction define FDA box warn , FDA cautionary labeling , clinical literature YouScript algorithm‐predicted significant effect : Amitriptyline ( Elavil ) , Aripiprazole ( Abilify ) , Atomoxetine ( Strattera ) , Carvedilol ( Coreg ) , Celecoxib ( Celebrex ) , Citalopram ( Celexa ) , Clobazam ( Onfi ) , Clomipramine ( Anafranil ) , Clopidogrel ( Plavix ) , Clozapine ( Clozaril ) , Codeine [ Tylenol # 3 ( combo ) ] , Desipramine ( Norpramin ) , Dextromethorphan ( Delsym ) , Diazepam ( Valium ) , Doxepin ( Sinequan ) , Escitalopram ( Lexapro ) , Esomeprazole ( Nexium ) , Fesoterodine ( Toviaz ) , Flecainide ( Tambocor ) , Fluoxetine ( Prozac ) , Flurbiprofen ( Ansaid ) , Fluvoxamine ( Luvox ) , Haloperidol ( Haldol ) , Hydrocodone ( Zohydro ) , Ibuprofen ( Motrin ) , Iloperidone ( Fanapt ) , Imipramine ( Tofranil ) , Indomethacin ( Indocin ) , Meloxicam ( Mobic ) , Metoprolol ( ToprolXL ) , Mexiletine ( Mexitil ) , Nortriptyline ( Pamelor ) , Omeprazole ( Prilosec ) , Oxycodone ( Oxycontin ) , Paroxetine ( Paxil ) , Perphenazine ( Trilafon ) , Phenobarbital ( Luminal ) , Phenytoin ( Dilantin ) , Pimozide ( Orap ) , Piroxicam ( Feldene ) , Proguanil [ ( Malarone ( combo ) ] , Propafenone ( Rythmol ) , Propranolol ( Inderal ) , Risperidone ( Risperdal ) , Sertraline ( Zoloft ) , Tetrabenazine ( Xenazine ) , Thioridazine ( Mellaril ) , Timolol ( Apotimol ) , Tolterodine ( Detrol ) , Torsemide ( Demadex ) , Tramadol ( Ultram ) , Trimipramine ( Surmontil ) , Venlafaxine ( Effexor ) , Voriconazole ( Vfend ) , Vortioxetine ( Brintellix ) For list inclusion criterion adapt `` untested '' patient ( retrospective cohort ) , see protocol . EXCLUSION CRITERIA : Patients ( prospective retrospective ) meeting follow criterion eligible enrollment/inclusion study ( ICD9 code include retrospective database patient ) : Previous CYP testing ( CPT cod 81225 , 81226 , 81227 ) History organ transplant ( 199.2 ; 238.77 ; 414.06 ; 414.07 ; 996.80‐996.89 ; E878.0 ; V42.0‐V42.7 ; V42.81‐V42.84 ; V42.89 ; V42.9 ; V45.87 ; V49.83 ; V58.44 ) Patient currently receive intravenous antibiotic Currently take immunosuppressant ( azathioprine , cyclosporine , monoclonal antibody , corticosteroid ) Current malabsorption syndrome ( 579.0 ) , include follow : Intestinal malabsorption ( 579.8 , 579.9 ) , Postoperative malabsorption ( 579.3 ) , Short bowel syndrome ( 579.3 ) Current hospitalization Treatment invasive solid tumor hematologic malignancy last year , exclude situ cancer nonmelanoma skin cancer ( basal cell carcinoma ) Currently malnourish , determine treat provider</criteria>
	<gender>All</gender>
	<minimum_age>65 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>Cytochrome drug interaction</keyword>
	<keyword>Drug-drug interaction</keyword>
	<keyword>Drug-gene interaction</keyword>
	<keyword>Drug-drug-gene interaction</keyword>
	<keyword>Drug Metabolism</keyword>
	<keyword>Elderly</keyword>
	<keyword>Geriatric medicine</keyword>
	<keyword>Geriatrics</keyword>
	<keyword>Personalized medicine</keyword>
	<keyword>Pharmacist</keyword>
	<keyword>Pharmacogenetics</keyword>
	<keyword>Pharmacogenomics</keyword>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Polymorphism</keyword>
	<keyword>Polypharmacy</keyword>
	<keyword>Precision medicine</keyword>
	<keyword>Seniors</keyword>
	<keyword>YouScript</keyword>
	<keyword>CYP2C9</keyword>
	<keyword>CYP2C19</keyword>
	<keyword>CYP2D6</keyword>
	<keyword>CYP3A4</keyword>
	<keyword>CYP3A5</keyword>
	<keyword>VKORC1</keyword>
	<keyword>Amitriptyline</keyword>
	<keyword>Aripiprazole</keyword>
	<keyword>Atomoxetine</keyword>
	<keyword>Carvedilol</keyword>
	<keyword>Celecoxib</keyword>
	<keyword>Citalopram</keyword>
	<keyword>Clobazam</keyword>
	<keyword>Clomipramine</keyword>
	<keyword>Clopidogrel</keyword>
	<keyword>Clozapine</keyword>
	<keyword>Codeine</keyword>
	<keyword>Desipramine</keyword>
	<keyword>Dextromethorphan</keyword>
	<keyword>Diazepam</keyword>
	<keyword>Doxepin</keyword>
	<keyword>Escitalopram</keyword>
	<keyword>Esomeprazole</keyword>
	<keyword>Fesoterodine</keyword>
	<keyword>Flecainide</keyword>
	<keyword>Fluoxetine</keyword>
	<keyword>Flurbiprofen</keyword>
	<keyword>Fluvoxamine</keyword>
	<keyword>Haloperidol</keyword>
	<keyword>Hydrocodone</keyword>
	<keyword>Ibuprofen</keyword>
	<keyword>Iloperidone</keyword>
	<keyword>Imipramine</keyword>
	<keyword>Indomethacin</keyword>
	<keyword>Meloxicam</keyword>
	<keyword>Metoprolol</keyword>
	<keyword>Mexiletine</keyword>
	<keyword>Nortriptyline</keyword>
	<keyword>Omeprazole</keyword>
	<keyword>Oxycodone</keyword>
	<keyword>Paroxetine</keyword>
	<keyword>Perphenazine</keyword>
	<keyword>Phenobarbital</keyword>
	<keyword>Phenytoin</keyword>
	<keyword>Pimozide</keyword>
	<keyword>Piroxicam</keyword>
	<keyword>Proguanil</keyword>
	<keyword>Propafenone</keyword>
	<keyword>Propranolol</keyword>
	<keyword>Risperidone</keyword>
	<keyword>Sertraline</keyword>
	<keyword>Tetrabenazine</keyword>
	<keyword>Thioridazine</keyword>
	<keyword>Timolol</keyword>
	<keyword>Tolterodine</keyword>
	<keyword>Torsemide</keyword>
	<keyword>Tramadol</keyword>
	<keyword>Trimipramine</keyword>
	<keyword>Venlafaxine</keyword>
	<keyword>Voriconazole</keyword>
	<keyword>Vortioxetine</keyword>
</DOC>